Comprehensive pharmacogenomic characterization of gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sa, Jason K. | - |
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Lee, In-Kyoung | - |
dc.contributor.author | Kim, Ju-sun | - |
dc.contributor.author | Sim, Moon-Hee | - |
dc.contributor.author | Kim, Ha Jung | - |
dc.contributor.author | An, Ji Yeong | - |
dc.contributor.author | Sohn, Tae Sung | - |
dc.contributor.author | Lee, Joon Ho | - |
dc.contributor.author | Bae, Jae Moon | - |
dc.contributor.author | Kim, Sung | - |
dc.contributor.author | Kim, Kyoung-Mee | - |
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Her, Nam-Gu | - |
dc.contributor.author | Lee, Yeri | - |
dc.contributor.author | Cho, Hee Jin | - |
dc.contributor.author | Shin, Yong Jae | - |
dc.contributor.author | Kim, Misuk | - |
dc.contributor.author | Koo, Harim | - |
dc.contributor.author | Kim, Mirinae | - |
dc.contributor.author | Seo, Yun Jee | - |
dc.contributor.author | Kim, Ja Yeon | - |
dc.contributor.author | Choi, Min-Gew | - |
dc.contributor.author | Nam, Do-Hyun | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.date.accessioned | 2021-08-31T09:45:35Z | - |
dc.date.available | 2021-08-31T09:45:35Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-02-18 | - |
dc.identifier.issn | 1756-994X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57626 | - |
dc.description.abstract | Background Gastric cancer is among the most lethal human malignancies. Previous studies have identified molecular aberrations that constitute dynamic biological networks and genomic complexities of gastric tumors. However, the clinical translation of molecular-guided targeted therapy is hampered by challenges. Notably, solid tumors often harbor multiple genetic alterations, complicating the development of effective treatments. Methods To address such challenges, we established a comprehensive dataset of molecularly annotated patient derivatives coupled with pharmacological profiles for 60 targeted agents to explore dynamic pharmacogenomic interactions in gastric cancers. Results We identified lineage-specific drug sensitivities based on histopathological and molecular subclassification, including substantial sensitivities toward VEGFR and EGFR inhibition therapies in diffuse- and signet ring-type gastric tumors, respectively. We identified potential therapeutic opportunities for WNT pathway inhibitors in ALK-mutant tumors, a significant association between PIK3CA-E542K mutation and AZD5363 response, and transcriptome expression of RNF11 as a potential predictor of response to gefitinib. Conclusions Collectively, our results demonstrate the feasibility of drug screening combined with tumor molecular characterization to facilitate personalized therapeutic regimens for gastric tumors. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | PHASE-II TRIAL | - |
dc.subject | METASTATIC BREAST-CANCER | - |
dc.subject | GENE-EXPRESSION | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | OPEN-LABEL | - |
dc.subject | TARGETED THERAPY | - |
dc.subject | PLUS PACLITAXEL | - |
dc.subject | MUTATIONS | - |
dc.subject | LANDSCAPE | - |
dc.subject | ADENOCARCINOMA | - |
dc.title | Comprehensive pharmacogenomic characterization of gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sa, Jason K. | - |
dc.identifier.doi | 10.1186/s13073-020-0717-8 | - |
dc.identifier.scopusid | 2-s2.0-85079791183 | - |
dc.identifier.wosid | 000517301700001 | - |
dc.identifier.bibliographicCitation | GENOME MEDICINE, v.12, no.1 | - |
dc.relation.isPartOf | GENOME MEDICINE | - |
dc.citation.title | GENOME MEDICINE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | METASTATIC BREAST-CANCER | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | TARGETED THERAPY | - |
dc.subject.keywordPlus | PLUS PACLITAXEL | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | LANDSCAPE | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Pharmacogenomics | - |
dc.subject.keywordAuthor | PIK3CA-E542K | - |
dc.subject.keywordAuthor | RNF11 | - |
dc.subject.keywordAuthor | Gefitinib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.